Table 1. Characteristics and pregnancy outcomes of the study population.

	Without Tenofovir		With Tenofovir
Characteristic	N (%)	Median (range)	N (%)	Median (range)
Age at delivery (years)	18	27.0 (18.1 – 42.0)	20	32.0 (22.2 – 45.1)
Weight at delivery (kg)	15	83.0 (65.9 – 133.7)	16	82.0 (56.7 – 159.1)
Weight postpartum (kg)	14	75.7 (53.1- 123.5)	19	82.2 (58.5 – 156.7)
CD4+ at delivery (cells/μL)	16	461.5 (242-1444)	20	472.5 (53 – 1494)
Race/ethnicity
Black	12 (67%)		8 (40%)
Hispanic	6 (33%)		7 (35%)
White	-----		3 (15%)
Other	-----		2 (10%)
Concomitant antiretrovirals*
Zidovudine + lamivudine	12 (63%)		3 (15%)
Zidovudine + lamivudine + abacavir	3 (16%)		-----
Lamivudine + abacavir	3 (16%)		1 (5%)
Emtricitabine	-----		16 (80%)
third trimester plasma HIV-1 RNA (copies/mL)	18	<62.5 (<50 - 19314)	19	<50 (<20 – 1630)
Undetectable (<20, 50, 75 or 400)	13 (72%)**		15 (79%)§
Detectable	5 (28%)		4 (21%)
Delivery plasma HIV-1 RNA (copies/mL)	16	<62.5 (<50 - 29933)	19	<75 (<20 – 116)
Undetectable (<20, 50, 75 or 400)	11 (69%)†		17 (89%)‡
Detectable	5 (31%)		2 (11%)
Postpartum plasma HIV-1 RNA (copies/mL)	11	<50 (,50 – 29933)	14	<75 (<20 - <400)
Undetectable (<20, 50, 75 or 400)	8 (73%)+		14 (100%)++
Detectable	3 (27%)		0
Pregnancy outcomes
Gestational age at delivery (weeks)	18	38.6 (36.3 – 41)	20	39.0 (35.7 – 41.4)
Birth weight (grams)	18	2917 (2320 – 4125)	20	2970 (2160 – 4260)

^*Other concomitant medications for atazanavir with tenofovir subjects included: didanosine, lamivudine, nelfinavir and fosamprenavir

^**9 subjects were < 50, 2 subjects were < 75, 2 subjects were <400

^§1 subject was <20, 10 subjects were <50, 4 subjects were <75

^†8 subjects were <50, 3 subjects were < 75

^‡1subject was <20, 8 subjects were <50, 5 subjects were <75, 3 subjects were <400

⁺6 subjects <50, 2 subjects <75

⁺⁺1 subject was <20, 5 subjects were <50, 4 subjects were <75, 4 subjects were <400